Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

• Status: Active, not recruiting
• Trial end date: 2024-01-10

Summary

This study study aims to elucidate the immune responses to a shared antigen vaccine (PROSTVAC) and tumor specific antigens generated DNA vaccine in combination with checkpoint blockade using nivolumab (anti-PD-1), and ipilimumab (anti-CTLA-4). Additionally, the investigators will study the impact of the combination immunotherapy on peripheral T cell activation, as well as immune response in the tumor microenvironment. Finally, the investigators will evaluate the safety and tolerability to this novel personalized immunotherapy in combination with checkpoint blockade.

• Phase: Phase 1

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborators: Bavarian Nordic; Bristol-Myers Squibb; Prostate Cancer Foundation; The Foundation for Barnes-Jewish Hospital
• Treatments: Antibodies, Monoclonal; Hormones; Ipilimumab; Nivolumab; Vaccines